Neurological adverse events following COVID-19 vaccination among Canadians referred to the special immunization clinic network

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2025-05-20 DOI:10.1016/j.vaccine.2025.127254

Tiffany Fitzpatrick , Peter Yamoah , David Summerby-Murray , Juthaporn Cowan , Manish Sadarangani , Alissa Wright , Sara Belga , Cora Constantinescu , Alex Carignan , Athena McConnell , Karina A. Top , on behalf of the Canadian Immunization Research Network Investigators

{"title":"Neurological adverse events following COVID-19 vaccination among Canadians referred to the special immunization clinic network","authors":"Tiffany Fitzpatrick , Peter Yamoah , David Summerby-Murray , Juthaporn Cowan , Manish Sadarangani , Alissa Wright , Sara Belga , Cora Constantinescu , Alex Carignan , Athena McConnell , Karina A. Top , on behalf of the Canadian Immunization Research Network Investigators","doi":"10.1016/j.vaccine.2025.127254","DOIUrl":null,"url":null,"abstract":"<div><div>Neurological adverse events have been reported rarely following COVID-19 vaccination. This study describes the characteristics of adolescents and adults assessed in the Canadian Special Immunization Clinic (SIC) Network for neurological adverse events following immunization (AEFIs) and outcomes of revaccination. Among 60 participants enrolled from January 2021 to February 2023, paresthesia/anesthesia was the most common diagnosis (15/60; 25.0 %), followed by Bell's Palsy (6/60; 10.0 %). Twenty-eight percent (17/60) of participants were hospitalized for their AEFI. Revaccination was recommended to 32/46 (69.6 %) participants due for subsequent doses when assessed in the SIC. Twenty-three participants were revaccinated and 4/23 (17.4 %) had recurrent symptoms of the AEFI; three were milder than the first event and none required hospitalization. Revaccination was generally safe in selected patients after a neurological AEFI. Expert assessment of patients with neurological AEFIs may help to support further vaccination.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"59 ","pages":"Article 127254"},"PeriodicalIF":4.5000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25005511","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Neurological adverse events have been reported rarely following COVID-19 vaccination. This study describes the characteristics of adolescents and adults assessed in the Canadian Special Immunization Clinic (SIC) Network for neurological adverse events following immunization (AEFIs) and outcomes of revaccination. Among 60 participants enrolled from January 2021 to February 2023, paresthesia/anesthesia was the most common diagnosis (15/60; 25.0 %), followed by Bell's Palsy (6/60; 10.0 %). Twenty-eight percent (17/60) of participants were hospitalized for their AEFI. Revaccination was recommended to 32/46 (69.6 %) participants due for subsequent doses when assessed in the SIC. Twenty-three participants were revaccinated and 4/23 (17.4 %) had recurrent symptoms of the AEFI; three were milder than the first event and none required hospitalization. Revaccination was generally safe in selected patients after a neurological AEFI. Expert assessment of patients with neurological AEFIs may help to support further vaccination.

查看原文本刊更多论文

加拿大人接种COVID-19疫苗后神经系统不良事件转介到特殊免疫诊所网络

COVID-19疫苗接种后很少报告神经系统不良事件。本研究描述了加拿大特殊免疫诊所（SIC）网络评估的青少年和成人免疫后神经不良事件（AEFIs）和再接种结果的特征。在2021年1月至2023年2月登记的60名参与者中，感觉异常/麻醉是最常见的诊断(15/60；25.0%)，其次是贝尔麻痹(6/60；10.0%)。28%（17/60）的参与者因AEFI住院。在SIC评估时，建议32/46（69.6%）的参与者再次接种疫苗。23名参与者再次接种疫苗，4/23（17.4%）有AEFI复发症状；其中3例比第1例轻，没有一例需要住院治疗。在选定的神经系统急性脑损伤后，重新接种疫苗通常是安全的。对神经系统急性脑损伤患者的专家评估可能有助于支持进一步的疫苗接种。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.